EA201591839A1 - Терапевтические пептиды - Google Patents

Терапевтические пептиды

Info

Publication number
EA201591839A1
EA201591839A1 EA201591839A EA201591839A EA201591839A1 EA 201591839 A1 EA201591839 A1 EA 201591839A1 EA 201591839 A EA201591839 A EA 201591839A EA 201591839 A EA201591839 A EA 201591839A EA 201591839 A1 EA201591839 A1 EA 201591839A1
Authority
EA
Eurasian Patent Office
Prior art keywords
therapeutic peptides
pyy
new
analogues
obesity
Prior art date
Application number
EA201591839A
Other languages
English (en)
Inventor
Стивен Томас Док
Эндрю Джеймс Карпентер
Роберт Нейл Хантер Третий
Юлинь Ву
Вед П. Сривастава
Original Assignee
Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед filed Critical Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед
Publication of EA201591839A1 publication Critical patent/EA201591839A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cell Biology (AREA)

Abstract

Настоящее изобретение относится к новым аналогам PYY, которые имеют улучшенный терапевтический профиль по сравнению с нативным PYY человека. Эти новые аналоги PYY являются полезными в лечении ожирения, диабета и других расстройств.
EA201591839A 2013-05-02 2014-04-30 Терапевтические пептиды EA201591839A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361818624P 2013-05-02 2013-05-02
PCT/IB2014/061123 WO2014178018A1 (en) 2013-05-02 2014-04-30 Therapeutic peptides

Publications (1)

Publication Number Publication Date
EA201591839A1 true EA201591839A1 (ru) 2016-05-31

Family

ID=50842285

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591839A EA201591839A1 (ru) 2013-05-02 2014-04-30 Терапевтические пептиды

Country Status (20)

Country Link
US (2) US9441023B2 (ru)
EP (1) EP2992008B1 (ru)
JP (1) JP2016519130A (ru)
KR (1) KR20160003848A (ru)
CN (1) CN105263957A (ru)
AR (1) AR096162A1 (ru)
AU (1) AU2014261111B2 (ru)
BR (1) BR112015027528B1 (ru)
CA (1) CA2909045C (ru)
CL (1) CL2015003199A1 (ru)
EA (1) EA201591839A1 (ru)
ES (1) ES2732291T3 (ru)
HK (1) HK1214829A1 (ru)
MX (1) MX2015015249A (ru)
PE (1) PE20151808A1 (ru)
RU (1) RU2015144632A (ru)
SG (1) SG11201508469YA (ru)
TW (1) TW201534616A (ru)
UY (1) UY35548A (ru)
WO (1) WO2014178018A1 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5902194B2 (ja) 2010-12-16 2016-04-13 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストとｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物
ES2952874T3 (es) 2012-03-22 2023-11-06 Novo Nordisk As Composiciones de péptidos GLP-1 y preparación de estas
TW201534616A (zh) * 2013-05-02 2015-09-16 Glaxosmithkline Ip Dev Ltd 治療性胜肽
JP6629198B2 (ja) 2013-11-15 2020-01-15 ノヴォ ノルディスク アー／エス ３５位にβ−ホモアルギニン置換を有するＨＰＹＹ（１−３６）
MX369818B (es) 2013-11-15 2019-11-22 Novo Nordisk As Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
WO2016124687A1 (en) * 2015-02-04 2016-08-11 Novo Nordisk A/S Selective pyy compounds and uses thereof
AR104984A1 (es) 2015-06-12 2017-08-30 Novo Nordisk As Compuestos selectivos para pyy y sus usos
BR112018013246A2 (pt) * 2015-12-28 2018-12-04 Idemitsu Kosan Co., Ltd. rótulo de peptídeo e proteína rotulada incluindo o mesmo
JOP20190095A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
CA3055759A1 (en) 2017-03-08 2018-09-13 Intarcia Therapeutics, Inc. Apparatus and methods for administration of a nauseogenic compound from a drug delivery device
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
US10875902B2 (en) 2018-04-25 2020-12-29 Janssen Pharmaceutica Nv Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
TWI749381B (zh) * 2018-11-01 2021-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
MX2022005661A (es) 2019-11-11 2022-09-07 Boehringer Ingelheim Int Agonistas del receptor npy2.
US20230071371A1 (en) * 2019-12-04 2023-03-09 The Scripps Research Institute Peptide conjugates and methods of use
EP4136102A1 (en) * 2020-04-17 2023-02-22 I2O Therapeutics, Inc. Long acting peptide tyrosine tyrosine (pyy) analogs and methods of use
CA3185637A1 (en) 2020-08-07 2022-02-10 Boehringer Ingelheim International Gmbh Soluble npy2 receptor agonists
WO2024038067A1 (en) 2022-08-18 2024-02-22 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists
CN117603364A (zh) * 2022-09-30 2024-02-27 广西医科大学附属肿瘤医院 一类GLP-1/glucagon/Y2受体三重激动剂及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
DK134189D0 (da) 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
WO1991011457A1 (en) 1990-01-24 1991-08-08 Buckley Douglas I Glp-1 analogs useful for diabetes treatment
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US6413539B1 (en) 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5612051A (en) 1995-11-17 1997-03-18 Yue; Samuel K. Method of treating involuntary muscle dysfunction with relaxin hormone
ATE417622T1 (de) 1996-08-08 2009-01-15 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
ES2293688T5 (es) 1997-08-08 2011-05-04 Amylin Pharmaceuticals, Inc. Nuevos compuestos análogos de la exendina.
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
JP2003522721A (ja) 1997-11-14 2003-07-29 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規なエキセンジンアゴニスト化合物
EP1032587B2 (en) 1997-11-14 2013-03-13 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
AU759058C (en) 1998-02-13 2005-09-15 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
DE60140625D1 (de) 2000-08-15 2010-01-07 Univ Illinois Verfahren zur herstellung von mikropartikeln
IL160983A0 (en) * 2001-09-24 2004-08-31 Imp College Innovations Ltd Use of pyy for preparation of a medicament for modification of feeding behavior
CA2555894A1 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
CN101027075A (zh) * 2004-09-24 2007-08-29 默克公司 用于治疗肥胖的组合疗法
BRPI0518559A2 (pt) * 2004-12-13 2008-11-25 Amylin Pharmaceuticals Inc motivos da famÍlia do polipetÍdeo pancreÁtico, polipeptÍdeos e mÉtodos compreendendo os mesmos
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
GB0504857D0 (en) * 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
WO2007112069A2 (en) * 2006-03-23 2007-10-04 Amylin Pharmaceuticals, Inc. Endothelin and endothelin receptor agonists in the treatment of metabolic diseases
CA2774552A1 (en) 2009-09-30 2011-04-07 Glaxo Group Limited Drug fusions and conjugates with extended half life
WO2011050008A2 (en) * 2009-10-19 2011-04-28 Amylin Pharmaceuticals, Inc. Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders
GB201001333D0 (en) * 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
JO3131B1 (ar) 2010-04-27 2017-09-20 Glaxosmithkline Llc مركبات كيميائية
WO2012006566A2 (en) * 2010-07-09 2012-01-12 Amylin Pharmaceuticals, Inc. Microcrystalline y receptor agonists
GB201101459D0 (en) * 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
TW201534616A (zh) * 2013-05-02 2015-09-16 Glaxosmithkline Ip Dev Ltd 治療性胜肽
MX369818B (es) * 2013-11-15 2019-11-22 Novo Nordisk As Compuestos selectivos de peptido yy (pyy) y usos de los mismos.

Also Published As

Publication number Publication date
CA2909045A1 (en) 2014-11-06
BR112015027528A2 (pt) 2017-12-05
RU2015144632A (ru) 2017-06-07
CA2909045C (en) 2022-12-06
PE20151808A1 (es) 2015-12-16
BR112015027528B1 (pt) 2023-02-14
US20140329742A1 (en) 2014-11-06
US9441023B2 (en) 2016-09-13
JP2016519130A (ja) 2016-06-30
HK1214829A1 (zh) 2016-08-05
ES2732291T3 (es) 2019-11-21
EP2992008B1 (en) 2019-04-10
TW201534616A (zh) 2015-09-16
AU2014261111B2 (en) 2017-03-16
UY35548A (es) 2014-11-28
AR096162A1 (es) 2015-12-09
MX2015015249A (es) 2016-02-09
WO2014178018A1 (en) 2014-11-06
KR20160003848A (ko) 2016-01-11
SG11201508469YA (en) 2015-11-27
CN105263957A (zh) 2016-01-20
US20160108098A1 (en) 2016-04-21
AU2014261111A1 (en) 2015-11-19
EP2992008A1 (en) 2016-03-09
CL2015003199A1 (es) 2016-05-06

Similar Documents

Publication Publication Date Title
EA201591839A1 (ru) Терапевтические пептиды
JOP20200192A1 (ar) أجسام مضادة لـ tigit
EA201690606A1 (ru) Аналоги глюкагона
EA201690494A1 (ru) Ацилированные аналоги глюкагона
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201590011A1 (ru) Пептидные аналоги эксендина-4
BR112016023948A2 (pt) proteínas fc multiméricas
EA201590294A1 (ru) Аналоги глюкагона
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201692109A1 (ru) Варианты антител к фактору d и их применение
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
BR112017005202A2 (pt) anticorpos anti-met e composições
CL2017000053A1 (es) Anticuerpos de unión a protofibrillas aß
CL2016000190A1 (es) Polipéptidos cíclicos para el tratamiento de la insuficiencia cardiaca.
EP3148569A4 (en) Therapeutic tratment of skin disease with recombinant commensal skin microorganisms
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
EA201791249A1 (ru) Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний
EA201691567A1 (ru) Способы лечения легких травм головного мозга
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
EA201890163A1 (ru) Композиция фолликулостимулирующего гормона млекопитающего с повышенной стабильностью
EA201700057A1 (ru) Терапевтическое применение белка, связывающегося с рецепторами нейротрофинов p75ntr
EA201591123A1 (ru) Комбинации агониста glp1r и метформина, а также способ их применения при лечении диабета 2 типа и прочих расстройств
EA201792560A1 (ru) Наночастицы для применения в качестве терапевтической вакцины